I agree about prioritization but the article I read suggested demand would outstrip current rate of facility growth for a while. Probably not for GBM but this is a platform treatment that is going to be in great demand off label too as well as others bringing their cell therapies into trials and to market. The article was about the big picture and is just something to keep an eye on because expected change is coming and for many it will be much sooner than they expect. Best wishes.
News 
Market Data 
Discover 
